natgillin/translations-raw huggingface dataset:
Linagliptin also showed significant improvements in fasting plasma glucose (FPG) by -21.1 mg/dl and 2-hour post- prandial glucose (PPG) by -67.1 mg/dl compared to placebo, as well as a greater portion of patients achieving a target HbA1c of < 7.0% (28.3% on linagliptin versus 11.4% on placebo).
Hkrati je linagliptin pomembno izboljšal raven glukoze v plazmi na tešče, in sicer za -21,1 mg/dl, in raven glukoze 2 uri po jedi, za -67,1 mg/dl v primerjavi s placebom, poleg tega je večji delež bolnikov dosegel ciljno raven HbA1c, ki je < 7,0 % (28,3 % pri linagliptinu, v primerjavi z 11,4 % pri placebu).
Linagliptin also showed significant improvements in fasting plasma glucose (FPG), and 2-hour post-prandial glucose (PPG) compared to placebo.
Pomembno je izboljšal tudi raven glukoze v plazmi na tešče in 2 uri po jedi v primerjavi s placebom.
Linagliptin as add-on therapy in patients with severe renal impairment, 12 week placebo-controlled data (stable background) and 40 week placebo-controlled extension (adjustable background)
Linagliptin kot dodatno zdravilo pri bolnikih s hudo ledvično okvaro, podatki o 12-tedenski, s placebom nadzorovani uporabi (stabilno osnovno zdravljenje) in o 40-tedenski, s placebom nadzorovani uporabi v podaljšku (prilagodljivo osnovno zdravljenje)
Linagliptin as add-on to a combination of metformin and sulphonylurea therapy
Linagliptin kot dodatno zdravilo k kombinaciji metformina in sulfonilsečnine
Linagliptin as add-on to a combination of metformin and sulphonylurea therapy
Linagliptin kot dodatno zdravilo ob kombinaciji metformina s sulfonilsečnino
Linagliptin as add-on to insulin therapy
Linagliptin kot dodatno zdravilo ob zdravljenju z insulinom
Linagliptin as monotherapy in patients ineligible for metformin
Monoterapija z linagliptinom pri bolnikih, za katere metformin ni primerno zdravilo
Linagliptin belongs to a class of medicines called DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors).
Linagliptin je zdravilna učinkovina iz skupine zaviralcev DPP-4 (zaviralci dipeptidil peptidaze-4).
Linagliptin binds very effectively to DPP-4 in a reversible manner and thus leads to a sustained increase and a prolongation of active incretin levels.
Linagliptin se zelo učinkovito reverzibilno veže na DPP-4, česar posledica je enakomerno zvišanje ravni aktivnega inkretina in podaljšanje njenega trajanja.
Linagliptin has no or negligible influence on the ability to drive and use machines.
Linagliptin nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
Linagliptin in combination with metformin and insulin
Linagliptin v kombinaciji z metforminom in insulinom
Linagliptin is an inhibitor of the enzyme DPP-4 (Dipeptidyl peptidase 4) an enzyme which is involved in the inactivation of the incretin hormones GLP-1 and GIP (glucagon-like peptide-1, glucose- dependent insulinotropic polypeptide).
Linagliptin je zaviralec DPP-4 (dipeptidil-peptidaze 4), encima, ki sodeluje pri inaktivaciji dveh inkretinskih hormonov GLP-1 in GIP (glukagonu podoben peptid 1, od glukoze odvisni insulinotropni polipeptid).
Linagliptin monotherapy
linagliptin samostojno
Linde Gaz Polska Sp. z o.o. ul. prof.
Linde Gaz Polska Sp. z o.o. al.Jana Pawła II 41a
Line the top of the base with the open end of the chamber.
Poravnajte vrh podnožja z odprtim koncem komore.
Line up the needle with the pen, and keep it straight as you attach it (screw or push on, depending on the needle type).
B.Naravnajte iglo z injekcijskim peresnikom in jo držite naravnost, medtem ko jo nameščate (privijte jo ali jo potisnite, odvisno od vrste igle).
Line up the needle with the pen, and keep it straight as you attach it (screw or push on, depending on the needle type).
Naravnajte iglo z injekcijskem peresnikom in jo držite naravnost, medtem ko jo nameščate (privijte jo ali jo potisnite, odvisno od vrste igle).
Line up the needle with the pen, and keep it straight as you attach it (screw or push on, depending on the needle type).
Naravnajte iglo z injekcijskim peresnikom in jo držite naravnost, medtem ko jo nameščate (privijte jo ali jo potisnite, odvisno od vrste igle).
Line up the syringe and vial
Poravnajte injekcijsko brizgo in vialo
Line up the two connection ports so that they are in a straight line.
Pritrditvena dela poravnajte tako, da sta v ravni črti.
Linear mixed PK-PD analyses indicated no large increase in mean QTcF interval (i.e., greater than 20ms) at daratumumab Cmax.
Linearna kombinirana analiza farmakokinetike in farmakodinamike pri Cmax daratumumaba ni pokazala večjega (več kot 20 ms) povečanja povprečnega intervala QTcF.
Linearity
Linearnost/Nelinearnost
Linearity / non-linearity
Linearnost/Nelinearnost
Linearity/ non linearity
Linearnost/Nelinearnost
Linearity/non-linearity:
Linearnost/Nelinearnost
Linearity/non-linearity: Rasagiline pharmacokinetics are linear with dose over the range of 0.5-2 mg.
Linearnost/ne-linearnost: Farmakokinetika razagilina je linearna pri odmerkih od 0,5 do 2 mg.
Linearity/non-linearity: The pharmacokinetics of adefovir are proportional to dose when given as adefovir dipivoxil over the dose range of 10 to 60 mg.
Linearnost/Nelinearnost: Farmakokinetične lastnosti adefovirja so sorazmerne odmerku vzetemu kot dipivoksiladefovirat v razponu odmerka od 10 mg do 60 mg.
Linearity: Studies in volunteers have demonstrated linear pharmacokinetics in the dose range of 10 to 40 mg.
Linearnost: Študije na zdravih prostovoljcih so pokazale, da ima memantin linearno farmakokinetiko v razponu odmerkov od 10 do 40 mg.
Linearity: Studies in volunteers have demonstrated linear pharmacokinetics in the dose range of 10 to40 mg.
Linearnost: Študije na zdravih prostovoljcih so pokazale, da ima memantin linearno farmakokinetiko v razponu odmerkov od 10 do 40 mg.
Lines of prior therapy = 1
Linije predhodnega zdravljenja =
Lines of prior therapy = 2 or 3
Linije predhodnega zdravljenja = 2 ali 3
linezolid (a medicine to treat bacterial infections) .
linezolid (zdravilo za zdravljenje bakterijskih okužb).
linezolid (a medicine to treat bacterial infections).
linezolid (zdravilo za zdravljenje bakterijskih okužb).
Lion Court, Farnham Road, Bordon Hampshire, GU35 0NF
Lion Court, Farnham Road, Bordon Hampshire, GU350NF
Lip inflammation
vnetje ustnic
Lip lesions, change of bowel habits, difficulty swallowing, mouth ulcer, heart burn, mouth pain, anal pain
ranice na ustnici, spremenjena pogostnost odvajanja blata, oteženo požiranje, razjede ustne sluznice, zgaga, bolečina v ustih, boleč zadnjik;
Lip oedema
edem ustnic
Lip swelling Swollen tongue
otekle ustnice otekel jezik
Lipase increased
povečana vrednost lipaze
Lipase increased
povečane vrednosti lipaze
Lipase increased
Zvišana raven lipaze
Lipase increased
zvišana vrednost lipaze
Lipase increased
zvišanje lipaze
Lipase increased
zvišanje ravni lipaze
lipase increased
zvišanje vrednosti lipaz
lipase inhibitors – used to treat obesity lipase in pancreatic replacement therapies
zaviralci lipaze – uporabljajo se za zdravljenje debelosti lipaze pri nadomestnih zdravljenjih bolezni trebušne slinavke
Lipegfilgrastim acts in the same way as naturally produced G‑CSF, increasing the production of neutrophils and thereby helping to reduce the duration of neutropenia and to prevent febrile neutropenia (a sign of infection) in patients undergoing chemotherapy.
Lipegfilgrastim deluje na enak način kot naravno nastali G-CSF, kar pomeni, da spodbuja tvorjenje nevtrofilcev in tako pomaga skrajšati trajanje nevtropenije in preprečiti febrilno nevtropenijo (ki je znak okužbe) pri bolnikih, ki prejemajo kemoterapijo
Lipegfilgrastim is a covalent conjugate of filgrastim with a single methoxy polyethylene glycol (PEG) molecule via a carbohydrate linker consisting of glycine, N-acetylneuraminic acid and
Lipegfilgrastim je kovalentni konjugat filgrastima z eno samo molekulo metoksipolietilenglikola (PEG), z veznim ogljikovim hidratom, sestavljenim iz glicina, N-acetilnevraminske kisline in
Lipegfilgrastim is similar to filgrastim, which has been available in the European Union (EU) for a number of years.
Lipegfilgrastim je podoben filgrastimu, ki je v Evropski uniji (EU) na voljo že vrsto let.
Lipid disorders should be managed as clinicallly appropriate.
Motnje lipidov je treba obravnavati klinično ustrezno.
LIPID LOWERING AGENTS
ZDRAVILA ZA ZMANJŠANJE RAVNI LIPIDOV
Lipid lowering agents
Zdravila za zniževanje lipidov
Lipid lowering agents
zmanjševanje odmerka v daljšem
Lipid Lowering Drugs
Zdravila za zniževanje ravni lipidov
LIPID LOWERING MEDICINAL PRODUCTS
ZDRAVILA ZA ZMANJŠANJE RAVNI LIPIDOV
LIPID LOWERING MEDICINAL PRODUCTS
ZDRAVILA ZA ZNIŽEVANJE RAVNI LIPIDOV
Lipid metabolism
Presnavljanje maščob
Lipid profiles should be determined prior to initiating Tasigna therapy, assessed at month 3 and 6 after initiating therapy and at least yearly during chronic therapy.
Vrednosti maščob v krvi je treba določiti pred začetkom zdravljenja z zdravilom Tasigna ter 3 in 6 mesecev po začetku zdravljenja, nato pa jih je med kroničnim zdravljenjem treba določati najmanj enkrat na leto.
lipid-lowering
zniževanje ravni lipidov
Lipid-lowering agents
Zdravila za zniževanje lipidov
LIPID-LOWERING MEDICINAL PRODUCTS
ZDRAVILA ZA ZMANJŠANJE RAVNI LIPIDOV
Lipids increased
zvišane vrednosti lipidov
lipids increased
zvišanje lipidov
Lipids, Change from baseline
Lipidi, sprememba v primerjavi z izhodiščno vrednostjo
Lipids: hyperlipidaemia has been identified as an effect associated with the use of bexarotene in clinical studies.
Lipidi: Hiperlipidemija je bila ugotovljena kot učinek, povezan z uporabo beksarotena v kliničnih študijah.
Lipoatrophy
lipoatrofija
lipoatrophy
lipoatrofija,
Lipodystrophy (thickening or pitting of the skin) is uncommon ( 1/1,000 to <1/100).
Lipodistrofija (zadebelitev ali vdolbina v koži) je občasen (≥1/1.000, <1/100) neželen učinek.
Lipodystrophy acquired
pridobljena lipodistrofija
Lipodystrophy at the injection site is uncommon (1/1,000 to <1/100).
Na mestu injiciranja insulina občasno (>1/1.000, <1/100) pride do lipodistrofije.
Lipodystrophy at the injection site is uncommon.
Na mestu injiciranja insulina občasno pride do lipodistrofije.
Lipodystrophy may occur at the injection site as a consequence of failure to rotate injection sites within an area.
Ce bolnik injekcijskih mest na posameznem predelu ne menja krožno, se lahko pojavi lipodistrofija.
Lipodystrophy:
Lipodistrofija
lipolytic activity: 40,000 units*
lipolitična aktivnost: 40.000 enot*,
Lipoprotein lipase is a key ‘first step’ enzyme in the metabolism of lipoproteins following fat intake with diet.
Lipoproteinska lipaza je ključni encim „prvega koraka“ pri presnovi lipoproteinov po vnosu maščobe s hrano.
Liposomal Amphotericin B
Amfotericin B v obliki liposomov
Liposomes vial: 1.9 ml
Viala z liposomi: 1,9 ml
Liposome–encapsulated doxorubicin corresponding to 50 mg doxorubicin hydrochloride
Liposomsko enkapsuliran doksorubicin, ki ustreza 50 mg doksorubicinijevega klorida
Liposome–encapsulated doxorubicin–citrate complex corresponding to 50 mg doxorubicin hydrochloride (HCl).
Kompleks doksorubicina in citrata, enkapsuliran v liposome, ki ustreza 50 mg doksorubicinijevega klorida (doksorubicin klorid).
Liprolog 100 units/ml KwikPen and Liprolog 200 units/ml KwikPen
Zdravili Liprolog 100 enot/ml KwikPen in Liprolog 200 enot/ml KwikPen
Liprolog 100 units/ml solution for injection in cartridge Insulin lispro (rDNA origin)
Liprolog 100 enot/ml raztopina za injiciranje v vložku insulin lispro (izdelan s pomočjo rekombinantne DNA)
Liprolog 100 units/ml solution for injection in vial insulin lispro
Liprolog 100 enot/ml raztopina za injiciranje v viali insulin lispro
Liprolog 100 units/ml solution for injection in vial Insulin lispro (rDNA origin)
Liprolog 100 enot/ml raztopina za injiciranje v viali insulin lispro (izdelan s pomočjo rekombinantne DNA)
Liprolog 100 units/ml, solution for injection in cartridge
Liprolog 100 enot/ml raztopina za injiciranje v vložku
Liprolog 100 units/ml, solution for injection in cartridge is made by:
Zdravilo Liprolog 100 enot/ml raztopino za injiciranje v vložku izdeluje:
Liprolog 100 units/ml, solution for injection in vial
Liprolog 100 enot/ml raztopina za injiciranje v viali
Liprolog 100 units/ml, solution for injection in vial is made by:
Zdravilo Liprolog 100 enot/ml raztopino za injiciranje v viali izdeluje:
Liprolog 100 units/ml, solution for injection is a sterile, clear, colourless, aqueous solution and contains 100 units of insulin lispro in each millilitre (100 units/ml) solution for injection.
Zdravilo Liprolog 100 enot/ml raztopina za injiciranje je sterilna, bistra, brezbarvna vodna raztopina in vsebuje 100 mednarodnih enot insulina lispro na mililiter (100 enot/ml) raztopine za injiciranje.
Liprolog 200 units/ml
Liprolog 200 enot/ml
Liprolog 200 units/ml KwikPen is used to treat diabetes.
Zdravilo Liprolog 200 enot/ml KwikPen uporabljamo za zdravljenje sladkorne bolezni.
Liprolog 200 units/ml KwikPen solution for injection should not be used in an insulin infusion pump.
Ne uporabljajte zdravila Liprolog 200 enot/ml KwikPen raztopina za injiciranje v insulinski infuzijski črpalki.
Liprolog 200 units/ml KwikPen, solution for injection is a sterile, clear, colourless, aqueous solution and contains 200 units of insulin lispro in each millilitre (200 units/ml) solution for injection.
Zdravilo Liprolog 200 enot/ml KwikPen raztopina za injiciranje je sterilna, bistra, brezbarvna vodna raztopina in vsebuje 200 mednarodnih enot insulina lispro na mililiter (200 enot/ml) raztopine za injiciranje.
Liprolog 200 units/ml solution for injection in pre-filled pen
Liprolog 200 enot/ml KwikPen raztopina za injiciranje v napolnjenem peresniku
Liprolog 200 units/ml solution for injection in pre-filled pen Insulin lispro
Liprolog 200 enot/ml raztopina za injiciranje v napolnjenem peresniku insulin lispro
Liprolog 200 units/ml solution for injection in pre-filled pen insulin lispro
Liprolog 200 enot/ml, raztopina za injiciranje v napolnjenem peresniku insulin lispro
Liprolog 200 units/ml, solution for injection in pre-filled pen insulin lispro
Liprolog 200 enot/ml raztopina za injiciranje v napolnjenem peresniku insulin lispro
Liprolog Basal
(motni insulin)
Liprolog Basal 100 units/ml KwikPen, suspension for injection
Liprolog Basal 100 enot/ml KwikPen suspenzija za injiciranje
Liprolog Basal 100 units/ml KwikPen, suspension for injection insulin lispro
Liprolog Basal 100 enot/ml KwikPen suspenzija za injiciranje insulin lispro
Liprolog Basal 100 units/ml KwikPen, suspension for injection Insulin lispro protamine suspension
Liprolog Basal 100 enot/ml KwikPen suspenzija za injiciranje Suspenzija insulina lispro-protamin
Liprolog Basal 100 units/ml KwikPen, suspension for injection is a white, sterile suspension and contains 100 units of insulin lispro in each millilitre (100 units/ml) suspension for injection.
Zdravilo Liprolog Basal 100 enot/ml KwikPen suspenzija za injiciranje je bela, sterilna suspenzija in vsebuje 100 mednarodnih enot insulina lispro na mililiter (100 enot/ml) suspenzije za injiciranje.
Liprolog Basal 100 units/ml KwikPen, suspension for injection is made by:
Zdravilo Liprolog Basal 100 enot/ml KwikPen suspenzijo za injiciranje izdeluje:
Liprolog Basal 100 units/ml suspension for injection in cartridge
Liprolog Basal 100 enot/ml suspenzija za injiciranje v vložku
Liprolog Basal 100 units/ml suspension for injection in cartridge insulin lispro
Liprolog Basal 100 enot/ml suspenzija za injiciranje v vložku insulin lispro
Liprolog Basal 100 units/ml suspension for injection in cartridge Insulin lispro protamine suspension
Liprolog Basal 100 enot/ml suspenzija za injiciranje v vložku Suspenzija insulina lispro-protamin
Liprolog Basal 100 units/ml suspension for injection in cartridge is made by:
Zdravilo Liprolog Basal 100 enot/ml suspenzijo za injiciranje v vložku izdeluje:
Liprolog Basal 100 units/ml suspension for injection is a white, sterile suspension and contains 100 units of insulin lispro in each millilitre (100 units/ml) suspension for injection.
Zdravilo Liprolog Basal 100 enot/ml suspenzija za injiciranje je bela, sterilna suspenzija in vsebuje 100 mednarodnih enot insulina lispro na mililiter (100 enot/ml) suspenzije za injiciranje.
Liprolog Basal can be mixed with or given in conjunction with Liprolog.
Zdravilo Liprolog Basal se lahko se lahko uporablja samostojno ali v kombinaciji s peroralnimi zdravili.
Liprolog Basal can be mixed with or given in conjunction with Liprolog.
Zdravilo Liprolog Basal se lahko uporablja samostojno, v kombinaciji s peroralnimi zdravili ali se meša z raztopino zdravila insulin lispro.
Liprolog Basal cartridges are not designed to allow any other insulin to be mixed in the cartridge .
Vložki zdravila Liprolog Basal so oblikovani tako, da onemogočajo mešanje kakih drugih insulinov v vložku.
Liprolog Basal cartridges are to be used with a CE marked pen as recommended in the information provided by the device manufacturer.
Vložke zdravila Liprolog Basal uporabljajte z injekcijskim peresnikom, označenim s CE, kot je priporočeno v podatkih izdelovalca pripomočka.
Liprolog Basal consists of insulin lispro protamine suspension.
Zdravilo Liprolog Basal vsebuje suspenzijo insulina lispro-protamin.
Liprolog Basal has a prolonged absorption profile, achieving a maximum insulin concentration approximately 6 hours after dosing.
Zdravilo Liprolog Basal ima podaljšan profil absorpcije in dosega največjo koncentracijo insulina približno 6 ur po odmerjanju.
Liprolog Basal has a prolonged mode of action compared to soluble insulin
Zdravilo Liprolog Basal ima v primerjavi z navadnim insulinom podaljšan način delovanja.
Liprolog Basal has a prolonged mode of action compared to soluble insulin.
Zdravilo Liprolog Basal ima v primerjavi z navadnim insulinom podaljšan način delovanja.
Liprolog Basal has an activity profile that is very
Liprolog Basal ima profil delovanja zelo podoben bazalnemu insulinu
Liprolog Basal has an activity profile that is very similar to that of a basal insulin (NPH) over a period of approximately 15 hours.
Zdravilo Liprolog Basal ima profil delovanja v obdobju približno 15 ur zelo podoben profilu delovanja bazalnega insulina (NPH).
Liprolog Basal has an activity profile that is very similar to that of a basal insulin (NPH) over a period of approximately 15 hours.
Zdravilo Liprolog Basal ima profil delovanja zelo podoben bazalnemu insulinu (NPH) v obdobju približno 15 ur.
Liprolog Basal is a substitute for your own insulin and is used to control glucose in the long term.
Zdravilo Liprolog Basal je nadomestek za telesu lasten insulin in ga uporabljamo za dolgoročno uravnavanje glukoze.
Liprolog Basal is a white, sterile suspension.
Zdravilo Liprolog Basal je bela, sterilna suspenzija.
Liprolog Basal is indicated for the treatment of patients with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.
Zdravilo Liprolog Basal je indicirano za zdravljenje bolnikov z diabetesom mellitusom, ki potrebujejo insulin za vzdrževanje normalne homeostaze glukoze.
Liprolog Basal is used to treat diabetes.
Zdravilo Liprolog Basal uporabljamo za zdravljenje sladkorne bolezni.
Liprolog Basal KwikPen is used to treat diabetes.
Zdravilo Liprolog Basal KwikPen uporabljamo za zdravljenje sladkorne bolezni.
Liprolog Basal should only be given by subcutaneous injection.
Zdravilo Liprolog Basal dajemo samo s subkutano injekcijo.
Liprolog Basal: insulin lispro protamine suspension;
Liprolog Basal: suspenzija insulina lispro-protamin;
Liprolog cartridges are to be used with a CE marked pen as recommended in the information provided by the device manufacturer.
Vložke zdravila Liprolog uporabljajte z injekcijskim peresnikom, označenim s CE, kot je priporočeno v podatkih izdelovalca pripomočka.
Liprolog is a sterile, clear, colourless, aqueous solution.
Zdravilo Liprolog je sterilna, bistra, brezbarvna vodna raztopina.
Liprolog is now available in 2 strengths
Zdravilo Liprolog je zdaj na voljo v 2 jakostih.
Liprolog is suitable for use in adults and children.
Zdravilo Liprolog je primeren tako za odrasle kot za otroke.
Liprolog is used to treat diabetes.
Zdravilo Liprolog uporabljamo za zdravljenje sladkorne bolezni.
Liprolog KwikPen 100 units/ml solution for injection insulin lispro
Liprolog 100 enot/ml KwikPen raztopina za injiciranje insulin lispro
Liprolog KwikPen 100 units/ml solution for injection Insulin lispro
Liprolog KwikPen 100 enot/ml raztopina za injiciranje insulin lispro
Liprolog KwikPen 100 units/ml solution for injection Insulin lispro (rDNA origin)
Liprolog KwikPen 100 enot/ml raztopina za injiciranje insulin lispro (izdelan s pomočjo rekombinantne DNA)
Liprolog KwikPen 100 units/ml, solution for injection
Liprolog 100 enot/ml KwikPen raztopina za injiciranje
Liprolog KwikPen 100 units/ml, solution for injection is a sterile, clear, colourless, aqueous solution and contains 100 units of insulin lispro in each millilitre (100 units/ml) solution for injection.
Zdravilo Liprolog 100 enot/ml KwikPen raztopina za injiciranje je sterilna, bistra, brezbarvna vodna raztopina in vsebuje 100 mednarodnih enot insulina lispro na mililiter (100 enot/ml) raztopine za injiciranje.
Liprolog KwikPen 100 units/ml, solution for injection is made by:
Zdravilo Liprolog 100 enot/ml KwikPen raztopino za injiciranje izdeluje:
Liprolog KwikPen is a sterile, clear, colourless, aqueous solution.
Zdravilo Liprolog KwikPen je sterilna, bistra, brezbarvna vodna raztopina.
Liprolog KwikPen is also indicated for the initial stabilisation of diabetes mellitus.
Zdravilo Liprolog KwikPen je indicirano tudi za začetno stabilizacijo diabetesa.
Liprolog KwikPen is used to treat diabetes.
Zdravilo Liprolog KwikPen uporabljamo za zdravljenje sladkorne bolezni.
Liprolog KwikPen takes effect rapidly and has a shorter duration of activity (2 to 5 hours) given subcutaneously as compared with regular insulin.
Subkutano dano zdravilo Liprolog KwikPen začne delovati hitro in deluje krajši čas (2 do 5 ur) v primerjavi z navadnim insulinom.
Liprolog may be used in children, when an advantage is expected compared to soluble insulin, for example, in the timing of the injection in relation to meals.
Pri otrocih ga lahko uporabimo, če pričakujemo prednost v primerjavi s topnim insulinom, na primer, kar zadeva čas injiciranja glede na obroke.
Liprolog Mix 25 consists of 25% insulin lispro solution and 75% insulin lispro protamine suspension.
Zdravilo Liprolog Mix25 vsebuje 25 % raztopine insulina lispro in 75 % suspenzije insulina lispro- protamin.
Liprolog Mix25 100 units/ml KwikPen suspension for injection
Liprolog Mix25 100 enot/ml KwikPen suspenzija za injiciranje
Liprolog Mix25 100 units/ml KwikPen suspension for injection 25% insulin lispro and 75% insulin lispro protamine suspension Subcutaneous use
Liprolog Mix25 100 enot/ml KwikPen suspenzija za injiciranje Suspenzija 25 % insulina lispro in 75 % insulina lispro-protamin Za subkutano uporabo
Liprolog Mix25 100 units/ml KwikPen suspension for injection insulin lispro
Liprolog Mix25 100 enot/ml KwikPen suspenzija za injiciranje insulin lispro
Liprolog Mix25 100 units/ml KwikPen, suspension for injection
Liprolog Mix25 100 enot/ml KwikPen suspenzija za injiciranje
Liprolog Mix25 100 units/ml KwikPen, suspension for injection is made by:
Zdravilo Liprolog Mix25 100 enot/ml KwikPen suspenzijo za injiciranje izdeluje:
Liprolog Mix25 100 units/ml suspension for injection in cartridge
Liprolog Mix25 100 enot/ml suspenzija za injiciranje v vložku
Liprolog Mix25 100 units/ml suspension for injection in cartridge 25% insulin lispro and 75% insulin lispro protamine suspension Subcutaneous use
Liprolog Mix25 100 enot/ml suspenzija za injiciranje v vložku Suspenzija 25 % insulina lispro in 75 % insulina lispro-protamin Za subkutano uporabo
Liprolog Mix25 100 units/ml suspension for injection in cartridge is made by:
Zdravilo Liprolog Mix25 100 enot/ml suspenzijo za injiciranje v vložku izdeluje:
Liprolog Mix25 cartridges are not designed to allow any other insulin to be mixed in the cartridge.
Vložki zdravila Liprolog Mix25 so oblikovani tako, da onemogočajo mešanje kakih drugih insulinov v vložku.